Selecta Biosciences (SELB) Tops Q4 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. AMGN
3. BKNG
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Selecta Biosciences (SELB) Tops Q4 EPS by 11c

Selecta Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 2, 2023 7:30 AM EST

- Topline data for Phase 3 DISSOLVE I & II clinical trials of SEL-212 in chronic refractory gout remains on track for Q1 2023 -

- Continue to enroll patients in ReiMMAgine, the Phase 1/2 clinical trial of SEL-302 for the treatment of methylmalonic acidemia (MMA) -

- IND enabling studies expected to commence in 2023 for interleukin-2 (IL-2) candidate to be studied in combination with ImmTOR, as well as IgA protease candidate for the treatment of IgA Nephropathy -

- As of December 31, 2022, Selecta... More